参一胶囊辅助化疗治疗晚期非小细胞肺癌临床观察

Clinical observation of treating non-small-cell lung cancer by chemotherapy and shenyi capsule

目的观察参一胶囊对非小细胞肺癌的辅助治疗作用。方法41例非小细胞肺癌通过双盲法,分为试验组22例,化疗(NP或MVP方案)+参一胶囊;对照组19例,化疗(NP或MVP方案)+安慰剂。结果与对照组相比,试验组患者的近期有效率、TTP、中位生存期和1年生存率分别为45.45%、6月、13月和68.18%,均明显高于对照组15.79%、3.4月、9月和36.84%,且有统计学上显著差异(P<0.05);毒副反应也较对照组轻,但无统计学上显著差异(P>0.05)。结论参一胶囊辅助化疗对非小细胞肺癌患者具有一定的增效减毒作用。

Objective ：To study the effect of Shenyi capsule on patients with non-small cell lung cancer（ NSCLC ）. Methods： Forty-one patients with pathologically confirmed NSCLC were treated double-blindly into chemotherapy plus shenyi capsule （Shenyi group） and chemotherapy plus placebo（ placebo group）. Results：Comparing the placebo group, response rate, time to progress（ TIP）, median survival time （MST） and 1 -year survival in shenyi group were 45.45 % ,6 months, 13 months and 68. 18 % , and those in placebo group were 15.79% ,3.4 months,9 months and 36. 84% , respectively. There was obviously statistical difference between two groups （ P 〈 0. 05 ）, and adverse reaction of chemotherapy in Shenyi group decreased comparing with placebo group, but no statistical difference was found. Conclusion ：The result show that Shenyi capsule combined with chemotherapy can enhance the therapeutic effect and detoxify the side effect of chemotherapy.